Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?

 
• By Joseph Haas and Jessica Merrill

Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what it might portend for biopharma M&A with Leerink Partners' Dan Lepanto and ZS partner Cody Powers.

Scrip Podcast Special
This edition of the Scrip M&A podcast focuses on US FTC oversight • Source: Shutterstock

More from Deals

More from Business